Both are weekly injectable medications that reduce appetite and slow digestion for sustainable weight loss. Semaglutide (Ozempic, Wegovy) targets one hormone pathway and produces roughly 15% body weight loss in clinical trials. Tirzepatide (Mounjaro, Zepbound) hits two pathways simultaneously and produces roughly 21% body weight loss — the highest ever recorded for a non-surgical weight loss drug. At Solace, both are available as part of a supervised medical program that includes labs, monitoring, and dose management by Dr. Flávio.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) is a hormone your small intestine naturally releases after eating. Its job is to signal fullness — it tells the brain you've had enough, slows how quickly food leaves your stomach, and suppresses appetite for several hours. In someone with obesity or metabolic disease, this hormone system is often underactive, making it harder to feel satisfied and easier to overeat.
GLP-1 receptor agonists are synthetic molecules designed to mimic and extend the effects of this natural hormone — but instead of lasting a few hours, a single weekly injection maintains the signal for seven full days. The result: persistent appetite suppression, significantly reduced caloric intake, and meaningful, sustained weight loss when combined with lifestyle changes.
Both semaglutide and tirzepatide work through this mechanism. The difference is what tirzepatide adds on top of it.
The GIP Factor — Why Tirzepatide Is Different
GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that amplifies insulin release after meals and plays a role in how the body stores and burns fat. Tirzepatide is the world's first dual GIP/GLP-1 receptor agonist — it activates both pathways simultaneously with a single injection.
The clinical significance of the dual mechanism is measurable: when GIP and GLP-1 work together, the appetite suppression is deeper, insulin sensitivity improves more substantially, and fat oxidation increases. This is likely why tirzepatide's clinical trials produced weight loss results approximately 40% greater than the best semaglutide trials.
Semaglutide — What the Data Shows
Semaglutide was developed by Novo Nordisk and first approved by the FDA in 2017 as Ozempic for type 2 diabetes management. Its weight loss benefits were significant enough that a higher-dose formulation — 2.4 mg weekly — received separate FDA approval in 2021 as Wegovy specifically for chronic weight management.
The landmark STEP 1 clinical trial (Wilding et al., NEJM 2021) followed 1,961 adults with obesity on 2.4 mg weekly semaglutide versus placebo over 68 weeks. Results: participants on semaglutide lost an average of 14.9% of body weight, compared to 2.4% for placebo. More than 70% of semaglutide patients lost at least 10% of their body weight — a threshold associated with meaningful improvements in blood pressure, cholesterol, and metabolic markers.
At Solace, semaglutide is administered via weekly subcutaneous injection, starting at a low dose and escalating gradually over 16–20 weeks to minimize gastrointestinal side effects. Compounded semaglutide is available for patients who cannot access or afford branded Wegovy.
Ideal candidate: Patients new to GLP-1 therapy, patients with a BMI of 27+ with a weight-related health condition, patients on a budget who want the more established option, or patients whose insurance covers semaglutide specifically.
Tirzepatide — What the Data Shows
Tirzepatide was developed by Eli Lilly and approved by the FDA in 2022 as Mounjaro for type 2 diabetes, then approved in 2023 as Zepbound specifically for chronic weight management — the first new obesity drug mechanism in over a decade.
The SURMOUNT-1 clinical trial (Jastreboff et al., NEJM 2022) followed 2,539 adults with obesity on tirzepatide (doses up to 15 mg weekly) versus placebo over 72 weeks. Results: participants on 15 mg tirzepatide lost an average of 20.9% of body weight — nearly 50 pounds on average. At lower doses (10 mg), average weight loss was 19.5%. More than 90% of tirzepatide patients lost at least 5% of body weight, and over a third lost 25% or more.
These are the highest weight loss figures ever recorded for a non-surgical obesity treatment in a randomized controlled trial. For context, bariatric surgery typically produces 25–30% body weight loss — tirzepatide at maximum doses begins to approach that range for high responders.
Ideal candidate: Patients who want the most aggressive pharmacological weight loss available, patients who have plateaued on semaglutide, patients with metabolic syndrome or insulin resistance who may benefit from the dual GIP/GLP-1 mechanism, and higher-BMI patients with more weight to lose.
Side-by-Side Comparison
| Semaglutide | Tirzepatide | |
|---|---|---|
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| FDA approval (obesity) | 2021 (Wegovy) | 2023 (Zepbound) |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist |
| Landmark trial | STEP 1 (NEJM 2021) | SURMOUNT-1 (NEJM 2022) |
| Average weight loss | ~14.9% at 68 weeks | ~20.9% at 72 weeks |
| Injection frequency | Once weekly | Once weekly |
| Dose escalation | 0.25 mg → 2.4 mg over 16+ weeks | 2.5 mg → 15 mg over 20+ weeks |
| Primary side effects | Nausea, constipation, diarrhea | Nausea, diarrhea, constipation |
| Solace pricing | From $299/mo | From $399/mo |
| Best for | First-time GLP-1 patients, budget-conscious | Maximum weight loss, plateaued patients |
Side Effects — What to Expect
Both medications share a similar side effect profile, driven by the GLP-1 mechanism: slowing gastric emptying means food sits in the stomach longer, which causes nausea, particularly in the first weeks of treatment and after dose increases. The most common side effects for both are:
- Nausea — most common early on; typically improves after the first 4–8 weeks
- Constipation — occurs in approximately 20–30% of patients; managed with fiber and hydration
- Diarrhea — less common than constipation; often related to dose escalation
- Fatigue — mild, usually transient in the first weeks
- Reduced appetite — this is the mechanism, not a side effect, but it can feel dramatic initially
Tirzepatide has shown slightly less nausea in some head-to-head comparisons, possibly because the GIP component partially offsets gastric side effects. However, the clinical significance of this difference is modest — both medications are well tolerated by the large majority of patients when dose escalation is managed properly.
At Solace, Dr. Flávio uses a conservative, gradual escalation protocol that significantly reduces early GI side effects. Patients are not rushed to the maximum dose — results come from the right dose for your body, not the highest possible dose.
What Happens When You Stop?
This is one of the most important questions — and the most honest answer is that weight regain is common when GLP-1 medications are discontinued without a maintenance plan. Studies tracking patients after stopping semaglutide show that most regain approximately two-thirds of lost weight within one year.
This doesn't mean the medication failed — it means obesity is a chronic condition that requires ongoing management, the same way hypertension requires ongoing blood pressure medication. The regain pattern after stopping GLP-1 therapy is now well-documented and has shifted how programs approach treatment. At Solace, the weight loss program includes a structured maintenance phase: as you approach your goal weight, Dr. Flávio works with you to find the minimum effective dose that maintains your results, rather than abruptly stopping treatment.
Fort Myers Pricing & What to Expect at Solace
Both medications are available at Solace Wellness Aesthetics as part of a supervised medical weight loss program:
- Semaglutide: Starting at $299/month. Includes medication, syringes, and provider oversight.
- Tirzepatide: Starting at $399/month. Includes medication, syringes, and provider oversight.
Every patient starts with an initial consultation and baseline labs with Dr. Flávio. The program includes:
- Comprehensive metabolic panel and lipid profile before starting
- Individualized dose escalation schedule based on your response and tolerance
- Monthly check-ins to review progress and adjust dosing
- Nutritional guidance and habit coaching alongside medication
- Structured maintenance phase to protect results long-term
This is not a "get-your-shot-and-leave" program. The difference in outcomes between supervised medical weight loss and unsupervised use is significant — proper dose management, side effect mitigation, and metabolic monitoring are what turn clinical trial results into real-patient results.
Our Recommendation
For most patients starting GLP-1 therapy at Solace, Dr. Flávio begins with semaglutide. It has the longer track record, more published data, and a slightly lower monthly cost. For many patients — particularly those with 30–50+ pounds to lose — semaglutide produces excellent, life-changing results.
Tirzepatide is the appropriate choice when maximum weight loss is the goal, when a patient has plateaued on semaglutide, or when metabolic markers (insulin resistance, high triglycerides, metabolic syndrome) suggest that the additional GIP mechanism will provide added benefit. The additional $100/month is a reasonable investment for the incremental efficacy — particularly for patients who have tried and stalled on other approaches.
The right starting point depends on your history, your labs, and your goals. Book a consultation below and Dr. Flávio will walk through both options with you before any prescription is written.
Wilding et al., NEJM 2021 (STEP 1 — semaglutide) and Jastreboff et al., NEJM 2022 (SURMOUNT-1 — tirzepatide).
STEP 1 Trial — NEJM →Frequently Asked Questions
Which is more effective for weight loss?
Tirzepatide produces consistently greater weight loss than semaglutide in clinical trials — approximately 21% vs. 15% of body weight. For a 200-pound person, that's roughly 42 pounds on tirzepatide vs. 30 pounds on semaglutide. The difference is driven by tirzepatide's additional GIP receptor activation. However, individual response varies — some patients respond exceptionally well to semaglutide, and there's no guarantee that tirzepatide will produce better results in every individual. Labs, metabolic history, and baseline insulin sensitivity all affect which medication performs better for a given patient.
Do tirzepatide side effects tend to be worse?
The side effect profiles are similar — both cause nausea, constipation, and GI discomfort during dose escalation. Some head-to-head comparisons suggest tirzepatide may cause slightly less nausea, possibly because the GIP component partially offsets gastric side effects. In practice, the difference is modest. Proper dose escalation — going slow and not rushing to the maximum dose — is more important than which medication you're on for managing side effects. At Solace, Dr. Flávio uses a conservative escalation protocol that minimizes early GI issues for both medications.
Can I switch from semaglutide to tirzepatide?
Yes — patients who have plateaued on semaglutide or want to try the more aggressive option can switch to tirzepatide. The transition requires restarting at a low tirzepatide dose to allow your system to adjust, rather than jumping to an equivalent dose. Dr. Flávio manages the transition schedule at Solace, typically including a brief washout or overlap period depending on where you are in your semaglutide protocol. Most patients who switch do see additional weight loss beyond their semaglutide plateau.
What happens when I stop the medication?
Studies consistently show that most patients regain a significant portion of lost weight — roughly two-thirds — within one year of stopping GLP-1 medications without a maintenance plan. This reflects the chronic nature of obesity as a condition, not a failure of the medication. At Solace, the program includes a structured maintenance phase: rather than abruptly stopping, Dr. Flávio works with patients approaching their goal weight to find the minimum effective maintenance dose, protecting results over the long term while minimizing ongoing cost and injection frequency.
Does insurance cover semaglutide or tirzepatide for weight loss?
Coverage is inconsistent and often limited for weight loss indications specifically. Branded Wegovy and Zepbound are approved for obesity but are excluded from many commercial insurance plans and most Medicare Part D formularies due to cost. Ozempic and Mounjaro (the diabetes-indication versions) may be covered if you have a type 2 diabetes diagnosis. Most patients at Solace pay out of pocket using compounded versions, which are significantly less expensive than branded products while using the same active ingredient. Dr. Flávio can walk through the options during your consultation.
How is Solace's program different from getting a prescription elsewhere?
Many telehealth and "weight loss clinic" models issue a prescription, ship the medication, and provide minimal follow-up. Solace's approach is fundamentally different: Dr. Flávio reviews baseline labs before starting, monitors metabolic markers throughout, manages dose escalation based on your actual response, provides nutritional guidance alongside medication, and plans a structured maintenance phase. The medication is a tool — the supervised program around it is what determines whether you achieve and sustain meaningful results. Patients who do this with proper medical oversight consistently outperform those on self-managed protocols.
Related Reading
Medical Weight Loss at Solace · Peptide Therapy · Semaglutide Guide · NAD+ Injections · Hormone Therapy